Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.30
-0.0610-4.49%
Volume:719.69K
Turnover:952.09K
Market Cap:83.54M
PE:-4.06
High:1.37
Open:1.36
Low:1.29
Close:1.36
52wk High:3.82
52wk Low:0.7708
Shares:64.31M
Float Shares:49.51M
Volume Ratio:1.79
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3200
EPS(LYR):-0.3200
ROE:-65.70%
ROA:-30.80%
PB:0.97
PE(LYR):-4.06

Loading ...

iBio initiated with an Outperform at Raymond James

TIPRANKS
·
Jun 08

Ibio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $6

THOMSON REUTERS
·
Jun 05

B. Riley Initiates iBio at Buy With $6 Price Target

MT Newswires Live
·
Jun 05

U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Honeywell, Tesla

Reuters
·
Jun 05

iBio executives present at Jefferies Global Healthcare Conference

Reuters
·
Jun 03

iBio to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire
·
Jun 03

iBio doses first patient in Phase 1 trial of obesity drug candidate IBIO-600

Reuters
·
Jun 02

Ibio Becomes a Clinical-Stage Company With First Participant Dosed in Phase 1 Clinical Trial of Ibio-600 in Adults With Obesity

THOMSON REUTERS
·
Jun 02

IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar

TIPRANKS
·
May 30

LifeSci Capital Remains a Buy on Ibio (IBIO)

TIPRANKS
·
May 16

iBio files Form 3 as director Elizabeth Stoner reports no beneficial ownership

Reuters
·
May 15

Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)

TIPRANKS
·
May 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)

TIPRANKS
·
May 13

BRIEF-Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update

Reuters
·
May 13

iBio reports Q3 EPS (7c), consensus (6c)

TIPRANKS
·
May 13

iBio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

iBio Q3 EPS $(0.07) Misses $(0.06) Estimate

Benzinga Earnings
·
May 13

iBio wins Australian clearance to start Phase 1 trial of obesity drug IBIO-600

Reuters
·
May 13

iBio FY26 Q3 net loss widens to $7.73 million; operating loss widens to $8.37 million

Reuters
·
May 13

Ibio Inc - Reports No Revenue for Q3 Ended March 31, 2026

THOMSON REUTERS
·
May 13